AtriCure Inc
NASDAQ:ATRC

Watchlist Manager
AtriCure Inc Logo
AtriCure Inc
NASDAQ:ATRC
Watchlist
Price: 30.52 USD 0.07%
Market Cap: 1.5B USD
Have any thoughts about
AtriCure Inc?
Write Note

AtriCure Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AtriCure Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
AtriCure Inc
NASDAQ:ATRC
Cash from Operating Activities
$10.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Cash from Operating Activities
$3.8B
CAGR 3-Years
-6%
CAGR 5-Years
3%
CAGR 10-Years
8%
Boston Scientific Corp
NYSE:BSX
Cash from Operating Activities
$2.9B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
10%
Stryker Corp
NYSE:SYK
Cash from Operating Activities
$3.8B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Cash from Operating Activities
$8.7B
CAGR 3-Years
-8%
CAGR 5-Years
10%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash from Operating Activities
$1.8B
CAGR 3-Years
-5%
CAGR 5-Years
6%
CAGR 10-Years
10%
No Stocks Found

AtriCure Inc
Glance View

Market Cap
1.5B USD
Industry
Health Care

Nestled in the heart of the highly competitive medical device industry, AtriCure Inc. has carved a significant niche for itself by focusing on the surgical treatment of atrial fibrillation, a common and potentially serious heart rhythm disorder. Founded in 2000 and headquartered in Mason, Ohio, AtriCure designs, manufactures, and sells an array of surgical devices aimed at improving treatment outcomes for this condition. The company’s innovative technology targets the complex network of electrical signals in the heart to restore regular rhythm and mitigate the risk of stroke—a common consequence of untreated atrial fibrillation. By providing surgeons with minimally invasive tools and advanced cryoablation and radiofrequency therapy systems, AtriCure not only addresses surgical efficiency but also enhances patient recovery times, distinguishing itself from its competitors. AtriCure derives its revenue from the sale of these sophisticated products directly to hospitals and surgical centers both in the United States and internationally. Key components of its portfolio include the Synergy Ablation System, which is acclaimed for its precision in creating lesions that block erratic electrical pathways, and AtriClip, a line of devices designed to occlude the left atrial appendage, thereby reducing stroke risk. As healthcare providers increasingly recognize the benefits of surgical intervention for atrial fibrillation over alternative treatments, AtriCure's financial health is buoyed by the rising adoption of its products. The company's strategic focus on expanding its product pipeline and enhancing its global sales footprint underscores its commitment to continuous growth and innovation in cardiac care.

ATRC Intrinsic Value
51 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is AtriCure Inc's Cash from Operating Activities?
Cash from Operating Activities
10.4m USD

Based on the financial report for Sep 30, 2024, AtriCure Inc's Cash from Operating Activities amounts to 10.4m USD.

What is AtriCure Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
1 980%

Over the last year, the Cash from Operating Activities growth was 1 980%.

Back to Top